Frequency of renal impairment, advanced age, obesity and cancer in venous thromboembolism patients in clinical practice

Journal of Thrombosis and Haemostasis

Volumn 5, Issue 5, 2007, Pages 937-941

  Cook, L M ^a   Kahn, Susan R ^a,b   Goodwin, J ^c   Kovacs, M J ^c  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c LONDON HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Cancer; Elderly; Low molecular weight heparin; Obesity; Renal impairment; Venous thrombosis

Indexed keywords

ANTICOAGULANT AGENT; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BODY WEIGHT; CANADA; CLINICAL FEATURE; CLINICAL PRACTICE; CONTROLLED STUDY; CREATININE CLEARANCE; DISEASE SEVERITY; DRUG DOSE REDUCTION; FEMALE; HUMAN; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MEDICAL DOCUMENTATION; MONOTHERAPY; MORBIDITY; OBESITY; PATIENT ASSESSMENT; POPULATION RESEARCH; PRESCRIPTION; PRIORITY JOURNAL; STATISTICAL ANALYSIS; VENOUS THROMBOEMBOLISM;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; FEMALE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; KIDNEY; MALE; MIDDLE AGED; NEOPLASMS; OBESITY; THROMBOEMBOLISM;

EID: 34247882903     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2007.02507.x     Document Type: Article

References (14)

1. Buller HR, Agnelli G, Hull RD, Hyers TM, Prins MH, Raskob GE. Antithrombotic therapy for venous thromboembolic disease: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 401S-428S.
2. Bazinet A, Almanric K, Brunet C, Turcotte I, Martineau J, Caron S, Blais N, Lalonde L. Dosage of enoxaparin among obese and renal impairment patients. Thromb Res 2005; 116: 41-50.
3. Lim W, Al Saleh K, Douketis JD. Low-molecular-weight heparins for the treatment of acute coronary syndrome and venous thromboembolism in patients with chronic renal insufficiency. Thromb Res 2006; 118: 409-16.
4. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis 2002; 39: S1-266.
5. Bates SM, Ginsberg JS. Clinical practice. Treatment of deep-vein thrombosis. N Engl J Med 2004; 35: 268-77.
6. Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 188S-203S.
7. Lim W, Dentali F, Eikelboom JW, Crowther MA. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med 2006; 144: 673-84.
8. Nagge J, Crowther M, Hirsh J. Is impaired renal function a contraindication to the use of low-molecular-weight heparin? Arch Intern Med 2002; 162: 2605-9.
9. Lopez-Jimenez L, Montero M, Gonzalez-Fajardo JA, Arcelus JI, Suarez C, Lobo JL, Monreal M. Venous thromboembolism in very elderly patients: findings from a prospective registry (RIETE). Haematologica 2006; 91: 1046-51.
10. Barba R, Marco J, Martin-Alvarez H, Rondon P, Fernandez-Capitan C, Garcia-Bragado F, Monreal M. The influence of extreme body weight on clinical outcome of patients with venous thromboembolism: Findings from a prospective registry (RIETE). J Thromb Haemost 2005; 3: 856-62.
11. Hainer JW, Barrett JS, Assaid CA, Fossler MJ, Cox DS, Leathers T, Leese PT. Dosing in heavy-weight/obese patients with the LMWH, tinzaparin: A pharmacodynamic study. Thromb Haemost 2002; 87: 817-23.
12. Al Yaseen E, Wells PS, Anderson J, Martin J, Kovacs MJ. The safety of dosing dalteparin based on actual body weight for the treatment of acute venous thromboembolism in obese patients. J Thromb Haemost 2005; 3: 100-2.
13. Caprini JA, Tapson VF, Hyers TM, Waldo AL, Wittkowsky AK, Friedman R, Colgan KJ, Shillington AC. Treatment of venous thromboembolism: adherence to guidelines and impact of physician knowledge, attitudes, and beliefs. J Vasc Surg 2005; 42: 726-33.
14. Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, Gent M. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349: 146-53.